Katarzyna Kazmierczak Selected Research

Ventricular Myosins

1/2021	Cardiomyopathic mutations in essential light chain reveal mechanisms regulating the super relaxed state of myosin.
8/2017	Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice.
1/2014	Remodeling of the heart in hypertrophy in animal models with myosin essential light chain mutations.
8/2013	Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy.
2/2012	Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice.
4/2009	Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice.
3/2009	Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katarzyna Kazmierczak Research Topics

Disease

13	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2021 - 02/2012
9	Familial Hypertrophic Cardiomyopathy (Cardiomyopathy, Familial Hypertrophic) 12/2014 - 03/2009
5	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2009
4	Cardiomegaly (Heart Hypertrophy) 01/2021 - 02/2012
3	Heart Diseases (Heart Disease) 01/2021 - 07/2015
3	Hypertrophy 12/2015 - 02/2012
2	Muscular Diseases (Myopathy) 12/2020 - 01/2019
1	Disease Progression 01/2021
1	Stroke (Strokes) 12/2020
1	Muscle Weakness 01/2019
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2018
1	Restrictive Cardiomyopathy 08/2017
1	familial dilated cardiomyopathy 06/2015
1	Lymphoma (Lymphomas) 06/2011
1	Dementia (Dementias) 10/2007
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2007
1	Inflammation (Inflammations) 10/2007

Drug/Important Bio-Agent (IBA)

15	Myosin Light Chains (Myosin Essential Light Chain)IBA 01/2021 - 10/2010
12	Myosins (Myosin)IBA 01/2022 - 01/2009
9	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2010
7	Ventricular MyosinsIBA 01/2021 - 03/2009
4	Cardiac MyosinsIBA 01/2021 - 07/2015
4	Alanine (L-Alanine)FDA Link 12/2015 - 12/2011
2	Arginine (L-Arginine)FDA Link 01/2019 - 01/2015
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 08/2013 - 12/2011
2	Valine (L-Valine)FDA Link 04/2012 - 03/2009
2	Aspartic Acid (Aspartate)FDA Link 04/2012 - 03/2009
1	MYK-461IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	CalciumIBA 01/2021
1	Protein Isoforms (Isoforms)IBA 12/2020
1	Adenosine Triphosphate (ATP)IBA 12/2020
1	Glutamine (L-Glutamine)FDA Link 01/2019
1	Polymethyl Methacrylate (Sol)IBA 01/2019
1	sarcalumeninIBA 12/2015
1	Carrier Proteins (Binding Protein)IBA 12/2015
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2015
1	Myosin-Light-Chain KinaseIBA 07/2015
1	Threonine (L-Threonine)FDA Link 01/2015
1	Troponin IIBA 01/2015
1	Cysteine (L-Cysteine)FDA Link 01/2015
1	Antiviral Agents (Antivirals)IBA 10/2007

Therapy/Procedure

1	Therapeutics 01/2021